ArticleBMC medical imaging2025
Evaluating modified ACR TI-RADS nodule size for thyroid nodules in pediatric population.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasonographic Evaluation of Pediatric Thyroid Nodules: Adult Risk Stratification Systems, 2021 K-TIRADS Revision, and Future Refinements.Korean journal of radiology · 2026Review
- Emotional burden of TI-RADS 4 thyroid nodules: clinical and psychosocial correlation.Gland surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we aimed to investigate the diagnostic performance of modified thyroid nodule size based on the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) for the pediatric population.
methodThis retrespective study enrolled patients younger than 21 years who underwent thyroid nodule US examination between January 2021 and June 2024. Thyroid nodules were assessed according to the ACR TI-RADS and the modification of size criteria. The diagnostic performance of sensitivity, specificity, area under the receiver operating characteristic curve (AUC), unnecessary biopsy rates, and missed malignancy rates were calculated and compared.
resultsA total of 204 thyroid nodules were retrospectively included, of them 51 were confirmed malignancies. For ACR TI-RADS, the sensitivity, specificity, and AUC were 76.5% (95% CI 62.5%-87.2%), 75.2% (95% CI 67.5%-81.8%), and 0.825 (95% CI 0.756-0.894), demonstrating moderate diagnostic performance. When applied modified lower nodule size, the sensitivity was improved (82.4%, 95% CI 69.1%-91.6%, and 88.2%, 95% CI 76.1%-95.6%); however, which was at the cost of decreasing specificity (65.4%, 95% CI 57.3%-72.9% and 53.6%, 95% CI 45.4%-61.7%).
conclusionACR TI-RADS demonstrated moderate diagnostic performance in the younger population. Lowering the thyroid nodule size criteria for FNAB leads to a higher detection rate of malignant, however, which at the cost of a significantly increased number of biopsies. Larger multicentric studies are required to customize the recommendation further before it can be accepted and used generally in the pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.